(Q44841343)

6 December 2017

title

Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease (English)

1 reference

6 December 2022

1 reference

6 December 2022

10

C D Marsden

1 reference

6 December 2017

P. A. Löschmann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835581

6 December 2022

K. W. Lange

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835581

6 December 2022

M. Kunow

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835581

6 December 2022

K. J. Rettig

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835581

6 December 2022

P. Jähnig

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835581

6 December 2022

T. Honoré

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835581

6 December 2022

L. Turski

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835581

6 December 2022

H. Wachtel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835581

6 December 2022

P. Jenner

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835581

6 December 2022

C. D. Marsden

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1835581

6 December 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1835581

6 December 2022

publication date

1 January 1991

1 reference

full work available at URL

6 December 2017

http://link.springer.com/content/pdf/10.1007/BF02259538.pdf

1 reference

http://link.springer.com/article/10.1007/BF02259538/fulltext.html

6 December 2022

1 reference

http://link.springer.com/content/pdf/10.1007/BF02259538

6 December 2022

1 reference

Journal of neural transmission. Parkinson's disease and dementia section

6 December 2022

published in

1 reference

6 December 2017

volume

3

1 reference

6 December 2017

issue

3

1 reference

6 December 2017

page(s)

203-213

1 reference

Reversal of experimental parkinsonism by lesions of the subthalamic nucleus

6 December 2017

cites work

1

1 reference

Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate

6 December 2022

2

1 reference

A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

6 December 2022

3

1 reference

Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice

6 December 2022

4

1 reference

Effects of classical and novel agents in a MPTP-induced reversible model of Parkinson's disease

6 December 2022

6

1 reference

Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey

6 December 2022

7

1 reference

Chronic parkinsonism secondary to intravenous injection of meperidine analogues

6 December 2022

8

1 reference

Glutamate: A Neurotransmitter in Mammalian Brain

6 December 2022

9

1 reference

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset

6 December 2022

10

1 reference

Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease

6 December 2022

11

1 reference

NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats

6 December 2022

12

1 reference

Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex

6 December 2022

15

1 reference

Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study

6 December 2022

16

1 reference

Pargyline Prevents MPTP-Induced Parkinsonism in Primates

6 December 2022

17

1 reference

Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437.

6 December 2022

18

1 reference

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

6 December 2022

19

1 reference

MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease

6 December 2022

20

1 reference

Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate

6 December 2022

21

1 reference

Anti-parkinsonian agents are phencyclidine agonists and N-methyl-aspartate antagonists

6 December 2022

22

1 reference

2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia

6 December 2022

25

1 reference

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

6 December 2022

27

1 reference

6-hydroxy-dopamine induced degeneration of central monoamine neurons

6 December 2022

28

1 reference

6 December 2022

Identifiers

DOI

10.1007/BF02259538

1 reference

release_2z2cf3fmkfasrcuju52jvc5uue

6 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2z2cf3fmkfasrcuju52jvc5uue

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference